Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection

Trial Profile

Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Aripiprazole lauroxil (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Alkermes plc
  • Most Recent Events

    • 18 Sep 2017 Primary endpoint has been met. (Change from baseline in Clinical Global Impressions-Severity (CGI-S) scores), according to an Alkermes plc media release
    • 18 Sep 2017 Positive 6-months topline results from this trial were presented at the 30th Annual Psych Congress (Psych Congress), according to an Alkermes plc media release
    • 18 Sep 2017 6-months results published in an Alkermes plc Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top